Core Viewpoint - Green Biological Technology Co., Ltd. (hereinafter referred to as Green Biological) is making another attempt to go public (IPO) after two previous unsuccessful attempts, amidst a renewed wave of IPOs in the cosmetics raw material sector [1][2][5]. Company Overview - Green Biological was established in December 1999, focusing on the research, production, and sales of bio-based and fully synthetic fragrances. Its product lines include turpentine, cedarwood oil, and various synthetic fragrances [2][5]. - The company is one of the largest suppliers of methyl cedryl ketone in China, with significant usage in household and high-end perfume products [2][5]. - The founder, Lu Wencong, holds 27.11% of the company's shares, and his daughter holds an additional 9%, making them the actual controllers of the company [6][7]. IPO Attempts - Green Biological's first IPO attempt began in 2018, but it was halted in early 2021 due to issues related to information disclosure and a significant expected drop in net profit [5][9]. - The second attempt in June 2023 also ended in withdrawal due to similar concerns raised by the Shenzhen Stock Exchange regarding environmental issues and innovation capabilities [5][9]. Financial Performance - The company has shown strong revenue growth, with revenues of 594 million, 631 million, and 735 million yuan from 2021 to 2023, representing growth rates of 6.23%, 16.48%, and a compound annual growth rate of 10.92% [9][10]. - Net profits for the same period were 201.7 million yuan, with growth rates of 65.85% and 32.35% in 2022 and 2023, respectively, leading to a compound growth rate of 48.43% [9][10]. - As of the end of 2023, total assets reached 1.433 billion yuan, with a net profit of 92.92 million yuan and a return on equity of 20.65% [10][11]. Market Context - The cosmetics raw material market in China is projected to grow from 1147.80 billion yuan in 2019 to 1603.90 billion yuan by 2024, with a compound annual growth rate of 6.9% [14]. - The recent surge in IPOs among raw material suppliers is attributed to the booming cosmetics industry and favorable regulatory changes, including the establishment of the Beijing Stock Exchange and reforms in the Sci-Tech Innovation Board [15][16][17]. - Green Biological's export revenue has been significant, accounting for over 84% of its main business from 2021 to 2023, with major clients including Procter & Gamble and other international raw material suppliers [11][12].

Core Viewpoint - Recently, the Zhejiang Securities Regulatory Bureau accepted the application for the initial public offering (IPO) and listing of Green Biological Technology Co., Ltd., with the filing date set for July 24, 2025, and the sponsoring institution being Changjiang Securities [1] Group 1: Company Background - Green Biological was established in 1999 and focuses on the research, production, and sales of fragrance products, forming three product series: turpentine oil, cedar oil, and fully synthetic fragrances [6] - The company has previously attempted to apply for an IPO on the ChiNext board, with its last application being withdrawn in September 2024 after multiple updates to the prospectus [5][6] Group 2: Financial Performance - The company's revenue for the years 2021, 2022, and 2023 was 594.38 million, 631.28 million, and 734.76 million yuan respectively, while the net profit attributable to the parent company was 40.74 million, 68.14 million, and 92.92 million yuan [6][7] - In the first quarter of 2024, the company reported a revenue of 238.09 million yuan, representing a year-on-year growth of 51.05%, and a net profit of 40.48 million yuan, showing a year-on-year increase of 123.45% [7] Group 3: Market and Clientele - The company's main export markets are Europe and North America, with foreign sales accounting for 84.38%, 85.95%, and 87.08% of total revenue in 2021, 2022, and 2023 respectively [8][9] - Major clients include Givaudan, Firmenich, and International Flavors & Fragrances (IFF), with sales to the top five customers accounting for 43.90%, 43.98%, and 40.51% of total revenue during the reporting periods [10] Group 4: Future Plans and Funding - The previous IPO application aimed to raise funds for projects including the annual production of 6,800 tons of high-grade fragrance, smart factory construction, and working capital supplementation, with a total planned fundraising of 375 million yuan [10][11] - The total investment for the high-grade fragrance project is estimated at 575.45 million yuan, with 217 million yuan planned to be raised from the IPO [11]